Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Executive Summary
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.
You may also be interested in...
Lilly Rides To Solid First Quarter On Diabetes, Newer Products
Smarting from a disappointing advisory committee review for baricitinib, Lilly pointed to the strong first quarter performance of its drugs launched since 2014, especially Trulicity.
Biogen Re-Ups With Ionis In Search Of A Neuroscience 'Innovation Engine'
New 10-year collaboration, the sixth between the two firms, will attempt to bring seven antisense candidates for neurological indications to the clinic in the next two years. Biogen pays $1bn up front, split between cash and Ionis equity.
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Roche’s Tecentriq IMpower150 trial showed Tecentriq plus Avastin plus paclitaxel and carboplatin significantly improved progression free survival compared to Avastin and chemo alone; overall survival data will be coming later this year.